Scope Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease
worldwide that can progress to liver fibrosis (LF). Probiotics have beneficial roles in reducing …

Nonalcoholic fatty liver disease (NAFLD) and its advanced stage, nonalcoholic
steatohepatitis (NASH), are the most common causes of chronic liver disease in the United …

Autoimmune hepatitis (AIH) is an immune-mediated type of chronic liver inflammation
accompanied by intestinal flora imbalance. Probiotics have been reported to ameliorate …

The microbiota–gut–liver axis has emerged as an important player in developing
nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease (NAFLD) …

Nonalcoholic steatohepatitis (NASH) is associated with imbalance of gut microbiome,
indicating participation of gut environment in hepatic health status. Therefore, modulating …

BACKGROUND Non‐alcoholic fatty liver disease (NAFLD) is becoming the most common
progressive liver diseases. Therapeutic strategy based on gut‐liver axis and probiotics is a …

Autoimmune hepatitis (AIH) is a liver disease characterized by chronic liver inflammation.
The intestinal barrier and microbiome play critical roles in AIH progression. AIH treatment …

As gut dysbiosis has been implicated in the pathogenesis of nonalcoholic steatohepatitis
(NASH), probiotic supplementation might be a potential treatment for this condition. The aim …

Gut microbiota dysbiosis plays an important role in the progression of non-alcoholic fatty
liver disease (NAFLD), and no approved drugs are available for NAFLD treatment. In this …

Background/aims Some studies showed that probiotics could improve the composition and
structure of gut microbiota. Changes in the gut microbiota may alter bile acid (BAs) …